Clinical validation of a novel quantitative assay for the detection of MGMT methylation in glioblastoma patients.

ABSTRACT:

Background

The promoter hypermethylation of the methylguanine-DNA methyltransferase gene is a frequently used biomarker in daily clinical practice as it is associated with a favorable prognosis in glioblastoma patients treated with temozolamide. Due to the absence of adequately standardized techniques, international harmonization of the MGMT methylation biomarker is still an unmet clinical need for the diagnosis and treatment of glioblastoma patients.

Results

In this study we carried out a clinical validation of a quantitative assay for MGMT methylation detection by comparing a novel quantitative MSP using double-probe (dp_qMSP) with the conventional MSP in 100 FFPE glioblastoma samples. We performed both technologies and established the best cutoff for the identification of

SUBMITTER: Rosas-Alonso R 

PROVIDER: S-EPMC7941980 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature